S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Georgia's largest county is still repairing damage from January cyberattack
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Georgia's largest county is still repairing damage from January cyberattack
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Georgia's largest county is still repairing damage from January cyberattack
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Georgia's largest county is still repairing damage from January cyberattack

Equillium (EQ) Competitors

$2.50
+0.01 (+0.40%)
(As of 03/1/2024 ET)

EQ vs. VCNX, ANVS, BTAI, ALLK, CMRX, IOBT, BRNS, DMAC, ETON, and CTMX

Should you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Vaccinex (VCNX), Annovis Bio (ANVS), BioXcel Therapeutics (BTAI), Allakos (ALLK), Chimerix (CMRX), IO Biotech (IOBT), Barinthus Biotherapeutics (BRNS), DiaMedica Therapeutics (DMAC), Eton Pharmaceuticals (ETON), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical preparations" industry.

Equillium vs.

Vaccinex (NASDAQ:VCNX) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Vaccinex has a net margin of 0.00% compared to Vaccinex's net margin of -19.28%. Vaccinex's return on equity of -29.28% beat Equillium's return on equity.

Company Net Margins Return on Equity Return on Assets
VaccinexN/A -2,667.31% -475.55%
Equillium -19.28%-29.28%-12.44%

Vaccinex has higher earnings, but lower revenue than Equillium. Equillium is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaccinex$280K27.81-$19.82M-$84.56-0.10
Equillium$15.76M5.57-$62.43M-$0.24-10.42

Vaccinex has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Equillium has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.

Vaccinex received 91 more outperform votes than Equillium when rated by MarketBeat users. However, 82.05% of users gave Equillium an outperform vote while only 60.00% of users gave Vaccinex an outperform vote.

CompanyUnderperformOutperform
VaccinexOutperform Votes
123
60.00%
Underperform Votes
82
40.00%
EquilliumOutperform Votes
32
82.05%
Underperform Votes
7
17.95%

Equillium has a consensus target price of $4.60, indicating a potential upside of 84.00%. Given Vaccinex's higher probable upside, analysts clearly believe Equillium is more favorable than Vaccinex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaccinex
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Equillium
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Vaccinex and Vaccinex both had 3 articles in the media. Equillium's average media sentiment score of 1.12 beat Vaccinex's score of 0.48 indicating that Vaccinex is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vaccinex
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Equillium
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 28.7% of Equillium shares are owned by institutional investors. 51.3% of Vaccinex shares are owned by insiders. Comparatively, 30.0% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Vaccinex and Equillium tied by winning 8 of the 16 factors compared between the two stocks.


Get Equillium News Delivered to You Automatically

Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EQ vs. The Competition

MetricEquilliumPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$87.80M$7.10B$5.19B$7.63B
Dividend YieldN/A2.84%2.82%3.87%
P/E Ratio-10.4210.47199.0614.81
Price / Sales5.57243.903,036.0080.43
Price / CashN/A18.9798.8355.35
Price / Book2.694.674.524.54
Net Income-$62.43M$155.80M$114.88M$211.55M
7 Day Performance-1.57%7.79%5.69%3.36%
1 Month Performance197.69%15.86%11.23%6.68%
1 Year Performance176.00%8.96%14.03%8.85%

Equillium Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VCNX
Vaccinex
2.2873 of 5 stars
$8.35
-19.6%
N/A-91.1%$104.29M$280,000.00-1.3838Stock Split
Short Interest ↓
Gap Down
High Trading Volume
ANVS
Annovis Bio
1.3084 of 5 stars
$10.07
-3.5%
$34.25
+240.1%
-47.8%$106.54MN/A-2.365Analyst Downgrade
BTAI
BioXcel Therapeutics
4.1276 of 5 stars
$3.51
flat
$23.57
+571.6%
-89.9%$106.63M$380,000.00-0.48183Short Interest ↑
ALLK
Allakos
4.7925 of 5 stars
$1.22
-2.4%
$9.42
+671.9%
-72.3%$106.73MN/A-0.64123Upcoming Earnings
Short Interest ↑
CMRX
Chimerix
4.5228 of 5 stars
$1.22
+6.1%
$8.00
+555.7%
-26.4%$108.45M$33.82M-1.2789Analyst Report
Analyst Revision
News Coverage
High Trading Volume
IOBT
IO Biotech
2.5971 of 5 stars
$1.54
-3.1%
$8.33
+441.1%
-32.0%$101.46MN/A-0.6357
BRNS
Barinthus Biotherapeutics
2.8134 of 5 stars
$2.61
+4.0%
$15.00
+474.7%
N/A$100.64M$44.70M-1.29107Short Interest ↓
News Coverage
High Trading Volume
DMAC
DiaMedica Therapeutics
1.4996 of 5 stars
$2.93
flat
$7.00
+138.9%
+77.5%$111.19MN/A-4.7316Gap Up
ETON
Eton Pharmaceuticals
3.9907 of 5 stars
$4.36
-0.9%
$10.00
+129.4%
+19.9%$111.88M$21.25M43.6028News Coverage
CTMX
CytomX Therapeutics
2.2296 of 5 stars
$1.47
flat
$2.73
+85.7%
+22.1%$98.48M$53.16M-3.27116Positive News

Related Companies and Tools

This page (NASDAQ:EQ) was last updated on 3/2/2024 by MarketBeat.com Staff